摘要
目的分析同期微创术治疗大肠癌合并肝脏转移患者的临床疗效。方法选取2016年7月至2017年7月本院收治的大肠癌并肝脏转移患者60例,按照随机数表法分为两组,每组30例。对照组给予同期腹腔镜与开腹联合手术,研究组给予同期微创术(腹腔镜下大肠癌根治手术与腹腔镜大部切除手术),比较两组患者临床效果、并发症及生存情况。结果治疗后,研究组出血量为(1 103.28±243.53)mL、手术时间为(510.52±118.59)min、输血量为(815.41±115.42)mL、排气时间为(73.25±7.52)h及首次下床时间为(6.92±0.84)d,为与对照组比较差异无统计学意义;研究组切口感染、胆汁淤积、胆瘘等并发症发生率(20.00%)与对照组(26.67%)比较差异无统计意义;研究组术后1年(100%)、2年生存率(96.67%)与对照组比较差异无统计意义。结论与同期腹腔镜与开腹联合手术比较,同期微创术治疗大肠癌合并肝脏转移患者手术时间与出血量比较差异无统计学意义,预后生存率良好,临床应用价值较高。
Objective To analyze the clinical effect of minimally invasive surgery for patients with colorectal cancer and liver metastasis.Methods From July 2016 to July 2017,60 patients with colorectal cancer and liver metastases were enrolled in our hospital.The patients were divided into two groups according to the random number table method,with 30 cases in each group.The control group was treated with concurrent laparoscopy and laparotomy,while the research group was treated with concurrent microsurgery(laparoscopic radical resection of colorectal cancer and laparoscopic subtotal resection).The clinical effect,complications and survival of the two groups were compared.Results After treatment,the bleeding volume of the study group(1103.28±243.53)mL,operation time(510.52±118.59)min,blood transfusion(815.41±115.42)mL,exhaust time(73.25±7.52)h and first time to get out of bed(6.92±0.84)d.The incidence of complications such as incision infection,cholestasis and bile fistula in the study group(20.00%)was not statistically significant compared with that in the control group(26.67%).The 1-year(100.00%)and 2-year survival rate(96.67%)of the study group were not statistically significant compared with the control group.Conclusion Compared with the simultaneous laparoscopy and laparotomy combined operation,the survival rate was good and the clinical application value is high.
作者
潘伯渠
Pan Boqu(First People's Hospital of Jinzhou District,Dalian,Liaoning,116100,China)
出处
《当代医学》
2020年第27期23-25,共3页
Contemporary Medicine
关键词
腹腔镜
同期手术
大肠癌
肝脏转移
并发症
生存
Laparoscopy
Concurrent surgery
Colorectal cancer
Liver metastasis
Complications
Survival
